Safety

News

Pressure is building on Amgen to withdraw rare disease therapy Tavneos, after the CHMP recommended its marketing authorisation by revoked in the EU.

R&D

Institutional Review Boards (IRBs) play a key role in evaluating scientific integrity and participant safety.

Oncology

CAR-NK cell therapies are frequently misunderstood, despite growing clinical and preclinical data supporting their potential.

News

Eli Lilly's ACHIEVE-4 trial results for oral GLP-1 Foundayo set up a filing in diabetes, and provide safety data sought by the FDA.

News

The FDA has laid out post-marketing safety testing requirements for Lilly's weight-loss pill Foundayo, including clinical trials.

News

The FDA has raised the pressure on Amgen to withdraw vasculitis drug Tavneos from the market with a report linking serious side effects to the drug.